Tucatinib side effects

In clinical studies of tucatinib in the treatment of HER2-positive metastatic breast cancer, the most common adverse reactions were diarrhea, palmoplantar red blood cell paresthesia, nausea, hepatotoxicity, vomiting, stomatitis, decreased appetite, anemia, and rash. Hepatotoxicity (1.5%) and diarrhea (1%) led to treatment interruption or reduction, and fatal adverse reactions occurred in 2% of cases, including sudden death, sepsis, dehydration and cardiogenic shock.

In clinical studies of tucatinib in the treatment of RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer, the most common adverse reactions were diarrhea, fatigue, rash, nausea, abdominal pain, infusion-related reactions, and fever. The most common laboratory abnormalities were elevated creatinine, glucose Elevated alanine aminotransferase, decreased hemoglobin, increased aspartate aminotransferase, increased bilirubin, increased alkaline phosphatase, lymphopenia, decreased albumin, leukopenia, and sodium decrease. Elevated alanine aminotransferase is an adverse reaction in patients who permanently discontinue tucatinib.

It is understood that the original drug Tucatinib has not yet been launched in China, so it has not entered the scope of domestic medical insurance. Patients in need cannot yet purchase this drug in pharmacies or hospitals. The price of the European version of tucatinib original drug sold overseas is around RMB 72,000 (the price may fluctuate due to exchange rates), which is expensive. There are also generic drugs of tucatinib produced in other countries. The price of Tucatinib produced by a Lao pharmaceutical factory is around 6,400 yuan (the price may fluctuate due to the exchange rate). The price is much cheaper than the original drug, and the ingredients of foreign generic drugs are basically the same as the original drug.